5407972026-01-012026-03-315407972026-03-315407972025-03-315407972025-04-012026-03-315407972026-01-012026-03-31in-capmkt:OtherExpenses1Member5407972026-01-012026-03-31in-capmkt:OtherExpenses2Member5407972026-01-012026-03-31in-capmkt:OtherExpenses3Member5407972026-01-012026-03-31in-capmkt:OtherExpenses4Member5407972025-04-012026-03-31in-capmkt:OtherExpenses1Member5407972025-04-012026-03-31in-capmkt:OtherExpenses2Member5407972025-04-012026-03-31in-capmkt:OtherExpenses3Member5407972025-04-012026-03-31in-capmkt:OtherExpenses4Member5407972026-03-31OtherNoncurrentFinancialAssetsDomain15407972026-03-31OtherNoncurrentAssetsDomain15407972026-03-31OtherNoncurrentAssetsDomain25407972026-03-31OtherCurrentFinancialAssetsDomain15407972026-03-31OtherCurrentAssetsDomain15407972026-03-31OtherNoncurrentFinancialLiabilitiesDomain15407972026-03-31OtherNoncurrentFinancialLiabilitiesDomain25407972026-03-31OtherNoncurrentLiabilitiesDomain15407972026-03-31OtherCurrentFinancialLiabilitiesDomain15407972026-03-31OtherCurrentFinancialLiabilitiesDomain25407972026-03-31OtherCurrentLiabilitiesDomain15407972026-01-012026-03-31in-capmkt:ReportableSegments1Member5407972026-01-012026-03-31in-capmkt:ReportableSegments2Member5407972025-04-012026-03-31in-capmkt:ReportableSegments1Member5407972025-04-012026-03-31in-capmkt:ReportableSegments2Member5407972026-01-012026-03-31in-capmkt:ReportableSegments1Member5407972026-01-012026-03-31in-capmkt:ReportableSegments2Member5407972025-04-012026-03-31in-capmkt:ReportableSegments1Member5407972025-04-012026-03-31in-capmkt:ReportableSegments2Member5407972026-01-012026-03-31in-capmkt:ReportableSegments1Member5407972026-03-31in-capmkt:ReportableSegments1Member5407972026-01-012026-03-31in-capmkt:ReportableSegments2Member5407972026-03-31in-capmkt:ReportableSegments2Member5407972026-01-012026-03-31in-capmkt:ReportableSegments1Member5407972026-03-31in-capmkt:ReportableSegments1Member5407972026-01-012026-03-31in-capmkt:ReportableSegments2Member5407972026-03-31in-capmkt:ReportableSegments2Member5407972026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15407972025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15407972026-01-012026-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15407972025-04-012026-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15407972026-01-012026-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares540797SHALBYNOTLISTEDINE597J01018SHALBY LIMITEDMain BoardEquity2025-04-012026-03-312026-05-272026-05-11INRMillionsQuarterlyFourth quarterMulti segment2026-05-2717:10:002026-05-2718:09:00trueCash Flow IndirectDeclaration of unmodified opinion2026-01-012026-03-31AuditedConsolidated2874450000807900002955240000149470000412480000-12714000049560000093380000184850000165054000028591800009606000009606000042290000-130770000-8848000001845400000000184540000-1441500004039000018318000013600003881000015600001075190000101.721.72001.721.72Notes to the Audited Consolidated Financial Results for the Quarter and Year ended as at March 31,2026 <BR> <BR> 1) The above Consolidated financial results for the quarter and year ended March 31, 2026 have been reviewed by the Audit Committee and subsequently approved by the Board of Directors of the company at their respective meetings held on May 27, 2026. The Statutory Auditors of the company have expressed unmodified opinion on the aforesaid results. <BR> <BR> 2) These financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under section 133 of Companies Act 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules 2015 and relevant amendment thereafter. <BR> <BR> 3) The figures for quarter ended 31st March, 2026 and for corresponding quarter ended 31st March, 2025 are the balancing figures between the audited figures in respect of the full financial year and the reviewed year-to-date figures up to the third quarter of the respective financial year. <BR> <BR> 4) Shalby Limited Employees Welfare Trust has acquired 7,00,000 Equity Shares of Shalby Limited in June 2022 pursuant to Employee Stock Option Scheme-2021. The company has granted all 7,00,000 Stock Options to eligible employees, out of which total 4,41,765 Stock Options were lapsed, 2,16,235 Options were vested and 2,09,235 Options exercised by eligible employees as on March 31, 2026 <BR> <BR> In accordance with the resolution passed by the Nomination and Remuneration Committee, the company has granted total 1,20,000 stock options from the pool of 4,41,765 lapsed options. As of March 31, 2026, a total of 1,16,000 stock options remain active. <BR> <BR> 5) Shalby Medtech Limited (“SMTL”) (Wholly Owned Subsidiary Company of Holding Company), have implemented Employee Stock Option Scheme, namely Shalby Medtech Limited - Employees Stock Options Scheme – 2025, as approved by its shareholders. During quarter ended March 31, 2026, SMTL has granted 10,91,000 Stock Options convertible into equivalent number of equity shares of SMTL upon vesting, pursuant to said ESOP scheme. <BR> <BR> 6) During the quarter ended March 31, 2026, the Group undertook an internal reorganization of its shareholding structure in respect of Shalby Advanced Technologies India Pvt Ltd, (SAT India) (step-down subsidiary of Shalby Limited) pursuant to which equity shares of the said step-down subsidiary were purchased by Shalby Medtech Limited from Shalby Advanced Technologies, Inc, USA (SAT Inc.). <BR> <BR> Pursuant to the aforesaid reorganization, Shalby Advanced Technologies India Pvt Ltd continues to remain a step down subsidiary of the Company with no change in the ultimate beneficial ownership and control of the said entity. Accordingly, the aforesaid restructuring has no material impact on the consolidated financial results of the Group. <BR> <BR> 7) The consolidated financial result includes the results of the Company and 13 Subsidiary companies (Covering 3 stepdown subsidiaies). The company together with its subsidiaries is herein referred to as the "Group". <BR> <BR> 8) The Company is not a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P /2018/144 dated 26th November, 2018. <BR> <BR> 9) The Holding Company has exercised the option of lower tax regime under Section 115BAA of the Income-tax Act, 1961 during the quarter ended March 31, 2026. Accordingly, the current tax and deferred tax balances have been remeasured/recomputed considering the applicable tax rate prescribed under the said section. The impact arising on account of such remeasurement/re-computation has been recognized in the Statement of Profit and Loss during the current quarter. <BR> <BR> The one-time tax impact on account of transition to the new tax regime is Rs. 340.16 Million recognized during the quarter ended March 31, 2026. Further, pursuant to the adoption of Section 115BAA, the Holding Company has written off MAT credit entitlement amounting to Rs. 42.36 Million during the quarter ended March 31, 2026. <BR> <BR> Further, during the quarter ended March 31, 2026, the Group undertook a periodic reassessment of deferred tax assets recognized in certain subsidiary companies amounting to Rs. 210.86 Million. Pursuant to this review and considering updated assumptions relating to future taxable profits, the carrying value of such deferred tax assets has been appropriately aligned in accordance with the Group’s prudent and conservative financial reporting approach. The corresponding accounting impact has been recognized in the Statement of Profit and Loss of the respective subsidiary entities for the quarter ended March 31, 2026. <BR> <BR> 10) On November 21, 2025, the Government of India notified the four labor codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as “the Labour Codes”). The Ministry of Labour and Employment published draft Central Rules and FAQs to enable the assessment of the financial impact due to changes in regulations. The Group has assessed the impact of changes in regulations and recognised a provision towards past service cost on gratuity and leave encashment payable to employees amounting to Rs. 6.86 Million during the year ended March 31, 2026, which is included under “Employee benefit expense”. The Group will continue to monitor the finalisation of Central/ State Rules and clarifications from the Government on other aspects of the Labour Code and will provide appropriate accounting effect of such events as needed. <BR> <BR> 11) As per Indian Accounting Standard ("Ind AS") 108 - "Segment Reporting", segment information has been provided in Consolidated Financial Results. The business segments of the company comprise of Medical and Healthcare Related Services & Manufacturing of Implant. Disclosure for the same is given in the separate note attached herewith in Annexure I. <BR> <BR> 12) During the quarter ended March 31, 2026, PK Healthcare Pvt Ltd, a subsidiary of the Holding Company, conducted a rights issue of equity shares in the ratio of 1:2 (one new equity share for every two equity shares held), at a par value of Rs.10/- per share. The Company subscribed to the rights issue to the extent of its entitlement. As a result, the Company's shareholding in PK Healthcare Pvt Ltd increased from 87.26% to 91.13%. <BR> <BR> The aforesaid transaction represents an increase in the Holding Company’s ownership interest in an existing subsidiary without any change in control. Accordingly, there is no material impact on the consolidated financial results of the Group, except for the consequential adjustment to non-controlling interests. <BR> <BR> 13) During the quarter ended March 31, 2026, Ningen Lifecare Private Limited, a step-down subsidiary of the company, filed an application with Ministry of Corporate Affairs ('MCA') for voluntary strike-off from the records of the Register of Companies in accordance with the applicable provisions of the Companies Act, 2013. MCA has approved the said application and accordingly, the said entity ceased to be a step-down subsidiary of the company with effect from 12th May, 2026, being the date of strike-off. <BR> <BR> The aforesaid strike-off does not have any material impact on the consolidated financial results / financial position of the Company <BR> <BR> 14) Previous period figures have been re-grouped, re-cast and re-arranged wherever considered necessary to make it comparable. <BR> <BR> 2025-04-012026-03-31AuditedConsolidated11414290000267910000116822000006479800001339370000-47435000018829300003899500006998700006590840000110765900006056100000605610000440210000-18147000025874000003468700000000346870000-24733000099540000373880000-27020000126340000-2681000010751900001089771500003.233.23003.233.23Materials and Consumables352820000Fees to Doctors and Consultants700210000Other Operative Expense232370000Other Expenses365140000Materials and Consumables1530570000Fees to Doctors and Consultants2759610000Other Operative Expense945730000Other Expenses1354930000922297000039300005685900006674100001841500000012388000012388000004270800001119801000037637900006226000002284240000219020000350000096140000322235000020713000071932700001839128000010751900008977150000100523400004590000100569300001528820000418500000194732000076400000485530000682000002577450000386736000051660000123320000012848600004105500005562770000149950000441800005756900000833435000018391280000Other Financial Assets123880000Income Tax Assets (Net)61960000Other non current assets365120000Other Financial Assets96140000Other Current Assets207130000Lease Liability414580000Other Financial Liabilities3920000Other Non-current Liabilities68200000Lease Liability135090000Other Financial Liabilities275460000Other Current liabilities149950000Healthcare Services2472320000Manufacturing of Implants402130000Healthcare Services10101370000Manufacturing of Implants1312920000287445000011414290000287445000011414290000Healthcare Services170770000Manufacturing of Implants-74710000Healthcare Services952820000Manufacturing of Implants-3472100009606000060561000096060000605610000Healthcare Services12649660000Manufacturing of Implants-4127940000852172000008521720000Healthcare Services5741630000Manufacturing of Implants-4206420000153521000001535210000389950000-606350000-562830000024360000-3530000631000021710000087360000010510000-1429000069987000000264100002468000000021800000000-753200000-2139300000-2068900003987200000003988000000-800000000000038090000149045000051819400004809970000000000000000000017160000090390000-9728400000032000000000154177000041276000025039000003506600000315830000844110000-1288100000-128810000347850000219040000Items that will not be reclassified to profit or loss38900003890000Items that will not be reclassified to profit or loss15400001540000490000-330000(Gain)/ Loss arising from translating the financial statement of foreign Operation-147550000-147550000(Gain)/ Loss arising from translating the financial statement of foreign Operation-249200000-24920000000-144150000-247330000AuditedtrueT R CHADHA & CO LLPtrue2028-09-30